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Letter to the Editor
VLDL-ASSOCIATED MUTAGENIC ACTIVITY
Received 11 November 1981
Sir,-In a recent issue of this Journal
Chan and Pollard (1981) report the
characterization of a VLDL-associated
cytotoxic factor. The cytotoxicity of
VLDL was not due to a number of lipids
carried by that lipoprotein, including
saturated and unsaturated free fatty
acids, unsaturated monoglycerides and
alcohols, steroid hormones, prostaglan-
dins and oxygenated derivatives of chol-
esterol such as 25-hydroxycholesterol. The
data suggested that the cytotoxic com-
ponent was associated with the neutral
lipid core of VLDL, but its identity was
not known..
The findings of Chan and Pollard may
tentatively be interpreted as supporting
our concept that VLDL is a major plasma
transporter of lipophilic xenobiotics with
cytotoxic and mutagenic/carcinogenic
activities.
In this connection it is noteworthy that
LDL and HLD have no cytotoxicity (Chan
& Pollard, 1978). In respect of the muta-
genicity associated with plasma lipo-
proteins it has been shown that in man
(Rueff & Halpern, 1982) VLDL was the
only mutagenic lipoprotein fraction in the
Salmonella/mammalian microsome assay,
and that the VLDL-associated muta-
genicity was not due to triglycerides, but
dependent on the particular exposure of
the individual to mutagenic/carcinogenic
compounds (e.g. smoking or occupational
exposure to mineral oils) (Gomes & Rueff,
unpublished). However, it has still to be
decided whether our observation of the
absence ofmutagenicity ofLDL and HDL
can be explained by any metabolic
mechanism. In fact, it has been demon-
strated (Shu & Nichols, 1979) that benzo-
(a)pyrene preferentially associates in
human plasma in vitro with VLDL and
LDL, but to a lesser extent with the for-
mer (29% vs 57%). This observation does
not however, rule out a metabolic explana-
tion. Cellular uptake of lipophilic xeno-
biotics seems to involve simple partition-
ing of these compounds between the
plasma lipoprotein and the cell membrane,
without the need of a specific process
involving cell receptors for LDL, and this
has been demonstrated for benzo(a)-
pyrene using LDL-receptor positive and
negative cells; the cellular uptake of the
carcinogen associated in vitro with LDL
was similar for both cell lines (Remsen &
Shireman, 1981).
Although both observations on the
mutagenicity and cytoxicity of lipopro-
teins show that both activities are re-
stricted to the VLDL fraction, it is not
possible with the available data to
conclude that a similar mechanism is
responsible for these 2 phenomena. The
fact that the study of Chan and Pollard
has been carried out using pregnant rat
lipoproteins, whereas ours uses human
lipoproteins, is the main drawback in
comparing the 2 activities. The VLDL-
associated cytotoxicity in pregnancy may
play a physiological role unrelated to the
mutagenicity observed in normal humans
exposed to environmental mutagens/
carcinogens. The only data we are aware
of concerning the cytotoxicity of normal
human serum also show that it concen-
trates in the lipoproteins (Luscher et al.,
1967). Yet the individual activity of each
lipoprotein fraction has not been studied.
Nevertheless, in the absence of further
data, a similar mechanism of preferential
uptake by VLDL of endogenous or exo-
genous lipophilic compounds cannot be
ruled out. Work is currently in progress in
this laboratory to obtain further informa-LETTER TO THE EDITOR 647
tion on this point, which may explain why
non-genetic factors seem to be important
in the variation ofVLDL levels. Exposure
to environmental lipophilic mutagens/
carcinogens is apparently one of those
factors.
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